BPI
RARE icon

BFC Planning, Inc.’s Ultragenyx Pharmaceutical RARE Stock Holding History

BFC Planning, Inc.’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13
Closed -$272 – 3494
2026
Q1 		$272 Hold
13
– – ﹤0.01% 2910
2025
Q4 		$299 Hold
13
– – ﹤0.01% 2998
2025
Q3 		$391 Buy
+13
New +$390 ﹤0.01% 2774

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

BFC Planning, Inc.'s RARE Position: Q2 2026 in Review

BFC Planning, Inc. sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 13 shares — an estimated $272 sold.

BFC Planning, Inc. first reported a position in RARE in Q3 2025 and held it in 3 quarters. The position peaked at $391 in Q3 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • BFC Planning, Inc. reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • BFC Planning, Inc. sold 13 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $272.
  • BFC Planning, Inc. first reported a position in Ultragenyx Pharmaceutical in Q3 2025 and held it in 3 quarters.
  • BFC Planning, Inc.'s Ultragenyx Pharmaceutical position peaked at $391 in Q3 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on BFC Planning, Inc.'s 13F filing for Q2 2026, filed 29 Oct 2026.